Q-omics provides the consensus-scored EGFLAM-AS4 profile across patient tissues and cancer cell-line models. EGFLAM-AS4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, EGFLAM-AS4 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, EGFLAM-AS4 RNA expression shows 6,440 significant protein co-abundance associations, with the highest sampling consensus in UCEC. Together, these results highlight CHOL, KIRC, and UCEC as cancer lineages where EGFLAM-AS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EGFLAM-AS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EGFLAM-AS4 survival associations across molecular data types. EGFLAM-AS4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EGFLAM-AS4 RNA expression–survival associations across cancer types. High EGFLAM-AS4 expression shows unfavorable associations in CHOL, SKCM, KIRC, BRCA and THYM, but favorable associations in LIHC. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for EGFLAM-AS4 RNA expression.
This table summarizes EGFLAM-AS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EGFLAM-AS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EGFLAM-AS4 shows higher tumor expression in KIRC, LUSC and LUAD. The KIRC box plot shows higher EGFLAM-AS4 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .023).
This table shows molecular features associated with EGFLAM-AS4 in patient tissues and cancer cell lines. In patient samples, EGFLAM-AS4 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
